KMT2A/MLLT3 t(9;11) Fusion probe hybridized to patient material showing t(9;11) translocation (2RG1R1G). Image kindly provided by Dr. Mohr, Dresden.
KMT2A/MLLT3 t(9;11) Fusion probe hybridized to patient material showing t(9;11) translocation (2RG1R1G). Image kindly provided by Dr. Mohr, Dresden.
IVD KMT2A/MLLT3
Chromosomal rearrangements involving the mixed lineage leukemia (MLL) gene at 11q23 are frequently observed in adult and childhood acute leukemia and are, in general, associated with poor prognosis. However, children with Acute Myeloid Leukemia (AML) carrying the t(9;11) KMT2A/MLLT3 (aka AF9) translocation have been described to be more sensitive to chemotherapy than patients with other 11q23 rearrangements. The KMT2A/MLLT3 Fusion FISH probe is optimized to detect translocations involving the KMT2A (previously known as MLL) and MLLT3 gene regions at 11q23 and 9p21 in a dual-color fusion assay on metaphase/interphase spreads, blood smears and bone marrow cells.
References: Von Lindern et al, 1992, Mol. Cell. Biol.,12; 1687-1697. Ageberg et al, 2008, Gen. Chrom. Canc., 47; 276-287. Chi et al, 2008, Arch. Pathol. Lab. Med.,132; 1835-1837.
Produkte
Produkte
KBI-10308
KMT2A/MLLT3 t(9;11) Fusion
Product is out of stock
Due to manufacturing & supply chain issues, this product is currently unavailable. You may place your order and it will be fulfilled when the product is back in stock. For more help, please reach out to customer service at +1 844 534 2262 or nonurgentcs@leicabiosystems.com
Product is limited in stock
Product availability is limited, but products are in continuous production. Your order will be processed as normal and may take additional days to ship.